Results 81 to 90 of about 577,308 (213)

UPD found in MDS/MPD-U patients both positive and negative for the JAK2 V617F mutation.

, 2013
UPD found in MDS/MPD-U patients both positive and negative for the JAK2 V617F mutation.
Andrew J. Dunbar (81782), Jaroslaw P. Maciejewski (81785), Lukasz P. Gondek (81781), Michael A. McDevitt (81784), Hadrian Szpurka (81783)   +4 more
core   +1 more source

A Therapeutic Dilemma: Catastrophic ST‐Elevation Myocardial Infarction Following Antiplatelet Therapy Interruption in a Patient With JAK2‐Positive Polycythemia Vera

Clinical Case Reports, Volume 14, Issue 8, August 2026.
Premature interruption of dual antiplatelet therapy in a patient with polycythemia vera and clinically suspected acquired von Willebrand syndrome triggered catastrophic recurrent stent thrombosis, whereas perioperative bridging with eptifibatide enabled safe surgery. ABSTRACT Polycythemia vera is associated with a thrombotic–hemorrhagic paradox.
Behrouz zarei, Amirhossein Rezaei Latifi, Mohammad Salari   +2 more
wiley   +1 more source

The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms

Hematology/Oncology and Stem Cell Therapy, 2015
CONTEXT AND OBJECTIVE: By using molecular markers, it is possible to gain information on both the classification and etiopathogenesis of chronic myeloproliferative neoplasias (MPN). METHODS: In a group of 27 Mexican mestizo patients with MPNs, we studied
Nancy Labastida-Mercado, Samantha Galindo-Becerra, Javier Garcés-Eisele, Perla Colunga-Pedraza, Valeria Guzman-Olvera, Virginia Reyes-Nuñez, Guillermo J Ruiz-Delgado, Guillermo J Ruiz-Argüelles   +7 more
doaj   +1 more source

From Basics to Benchmarks: Evaluating Sample Adequacy, PD‐L1 Expression, and Molecular Profiling in Effusion Samples of Lung Adenocarcinoma

Diagnostic Cytopathology, Volume 54, Issue 8, Page 547-555, August 2026.
ABSTRACT Introduction Lung adenocarcinoma commonly causes malignant pleural effusion (MPE), a condition with poor prognosis and limited treatment options. Pleural effusion specimens offer a minimally invasive source for diagnosis and molecular testing.
Harpreet Virk, Claire Michael, Keri Ann Pfeil, Navid Sadri, Omid Savari, Aparna Harbhajanka   +5 more
wiley   +1 more source

The frequency of JAK2 V617F gen mutation and its associations with whole blood count parameters

, 2014
Objective: V617F mutation of Janus kinase (JAK2) gene is used in the diagnosis of BCR-ABL negative myeloproliferative diseases such as polycytemia vera, essential thrombocythemia and primary myelofibrosis.
Yilmaz, Fatma Meric, ÜNAL, KÜBRANUR, Erdogan, Serpil   +2 more
core   +1 more source

The thrombopoietin receptor S264F mutant drives MPN with marrow fibrosis through a dual mechanism

HemaSphere, Volume 10, Issue 10, October 2026.
Charlotte Lees, Emile Brandt, Emmanuel Dutranoix, Gabriel Levy, Bogdan I. Iorga, Hosuk Ryou, Jens Rittscher, Daniel Royston, Stefan N. Constantinescu, Adam J. Mead   +9 more
wiley   +1 more source

JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients

Folia Histochemica et Cytobiologica, 2011
The recently discovered JAK2 V617F point mutation, found in 50–60% of ET patients, has been reported to be associated with a higher risk of thrombotic events.
Anna Dmoszyńska, Martyna Kandefer-Szerszeń, Anna M. Kowalska, Tomasz Gromek, Adam Walter-Croneck, Katarzyna Wejksza, Sylwia Chocholska, Ksenia Bykowska, Aleksandra Nowaczyńska, Bożena Sokołowska   +9 more
doaj   +1 more source

The V617F mutation of JAK2 is very uncommon in patients with thrombosis

Haematologica, 2007
Given that many cases of thrombosis do not have a clear cause, a myeloproliferative disease could be involved. We investigated the V617F mutation of the JAK2 gene in 295 patients with thrombosis. Only one case was positive. Therefore, the study of this mutation is not necessary in all patients with idiopathic thrombosis.
Angel F. Remacha, Camino Estivill, M. Pilar Sarda, José Mateo, Joan Carles Souto, Carme Canals, Josep Nomdedéu, Jordi Fontcuberta   +7 more
openaire   +3 more sources

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

, 2008
An acquired somatic mutation in the JAK2 gene (JAK2-V617F) is present in the majority of patients with myeloproliferative disorders (MPDs). Several phenotypic manifestations (polycythemia vera [PV], essential thrombocythemia [ET], and primary ...
Sobas, Marta A., Tiedt, Ralph, Looser, Renate, Dirnhofer, Stephan, Schwaller, Jürg, Skoda, Radek C., Hao-Shen, Hui, Hao-Shen H, Tiedt R, Dirnhofer S, Sobas MA, Skoda RC, Schwaller J, Looser R   +13 more
core   +1 more source

Immune Effector Cell‐Associated Hematotoxicity With Secondary Myelofibrosis Following Idecabtagene‐Vicleucel for Multiple Myeloma, Comprehensively Treated With Autologous Hematopoietic Stem Cell Boosting

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Pancytopenia accompanied by chimeric antigen receptor T cell (CAR‐T) therapy is termed immune effector cell‐associated hematopoietic toxicity (ICAHT), which is often sustained and refractory to supportive care. We report a case of a 52‐year‐old man with multiple myeloma who developed severe ICAHT with secondary myelofibrosis (sMF) after ...
Keishi Ogura, Takahiro Fujino, Takahisa Nakamura, Akihiro Miyashita, Akio Onishi, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Shinichi Fuchida, Junya Kuroda   +9 more
wiley   +1 more source